"LTR Pharma (ticker LTP on the ASX) was not included in the MSCI Australia Index during the latest November 2024 review. This recent MSCI adjustment primarily incorporated other sectors and did not feature new biopharma additions like LTR Pharma. Currently, LTR Pharma focuses on the commercialization of its primary product, SPONTAN®, a nasal spray for erectile dysfunction, aiming for faster absorption rates compared to traditional oral treatments. The company has made progress in its clinical trials and plans regulatory submissions in both Australia and the United States."
Maybe the guy who made the claim can post a link (like they should have in the first place)?
LTP Price at posting:
$1.48 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)